Uveitis can be caused by various systemic diseases and the association of viral hepatitis with uveitis has been proposed.^[@R1]--[@R7]^ Among all the causes of viral hepatitis, hepatitis B^[@R8],[@R9]^ and C^[@R10]--[@R12]^ are quite common and noteworthy problems in Taiwan and all over the world. Chronic viral hepatitis B, C, and D, and so on can lead to liver cirrhosis, which refers to a group of chronic liver diseases in which normal liver cells are damaged and replaced by scar tissue, decreasing the amount of normal liver tissue. Patients with hepatitis complicated with liver cirrhosis have been noted with higher aqueous flare values than noncirrhosis subjects.^[@R4]^

In the literature, few published reports have addressed the relationship between viral hepatitis, liver cirrhosis, and the potential risk of uveitis. Also, the estimated association between viral hepatitis, liver cirrhosis, and uveitis remains unresolved. In this study, we conducted a nationwide cohort study to measure the association by analyzing the claims data from the Taiwan National Health Insurance Research Database (NHIRD) during a follow-up period from 2000 to 2011 to with *International Classification of Diseases, Ninth Revision* (*ICD-9*) codes used to identify the correlation among these diseases in a Taiwanese population.

Patients and Methods {#s1}
====================

Data Source {#s1-1}
-----------

Taiwan\'s Bureau of National Health Insurance set up the NHIRD based on the single-payer National Health Insurance program. This program was inaugurated on March 1, 1995 and provides coverage to more than 99% of all residents in Taiwan. We obtained a Longitudinal Health Insurance Database, a part of the NHIRD, which includes 1 million insurants randomly selected from the 2000 Registry for Beneficiaries. All medical claims included both inpatient and outpatient visits and medical treatment for each insurant from the start of 1996 to the end of 2011 that were contained in the Longitudinal Health Insurance Database. To comply with the Personal Information Protection Act, the identification of each insurant in the Longitudinal Health Insurance Database was recoded. This study was also approved by the Institutional Review Board of China Medical University Hospital, Taiwan.

Study Subject {#s1-2}
-------------

We collected data of patients who were newly diagnosed with viral hepatitis (*ICD-9*, Clinical Modification \[*ICD-9-CM*\] 070.XX and V02.6X) from 2000 to 2011. People with at least 3 medical visits for viral hepatitis were defined as a new case and the first visit date for viral hepatitis was defined as the index date. Although the data collection period was from 2000 to 2011, we have traced back and checked all their medical records to make sure that no previous diagnosis of viral hepatitis was made even before 2000. Those with a history of uveitis (*ICD-9-CM* 360.00, 360.11, 360.12, 362.18, 363.00, 363.01, 363.03, 363.05--363.08, 363.1x, 363.20, 363.21, 363.4x, 364.00--364.02, 364.04 and 364.1x--364.3x), or were younger than 20 years were excluded. Patients with interferon treatment, human immunodeficiency virus infection, tuberculosis, syphilis, or autoimmune diseases were also excluded. Subjects without medical visit for eye diseases were also excluded.

Controls were randomly selected from people without viral hepatitis, interferon treatment, human immunodeficiency virus infection, tuberculosis, syphilis, or uveitis history. They were frequency matched by age group (20--24 years, 25--29 years, 30--34 years old and so on), gender, monthly income, occupation, ophthalmologic outpatient department (OPD) before the index date and index-year at a ratio 2:1. We included only patients with at least one medical visit for ophthalmology before enrolling into the study. After this restriction, we matched the ophthalmologic OPD visits between both the groups.

End point, Demographic Characteristics, and Viral Hepatitis Type {#s1-3}
----------------------------------------------------------------

The interested end point was uveitis diagnosis. People with at least twice medical visits for uveitis, which was separated for at least 7 days, were defined as the end point to ensure the validity. All study subjects were followed from the index date until when the end point occurred. Those without endpoint development were followed until the date of withdrawal from the program or the end of 2011, whichever occurred first. In this study, the demographic characteristics included age group (20--29 years, 30--39 years, 40--49 years, 50--59 years, and 60 years and older), gender, occupation (white collar, blue collar and others), monthly income (\<486, 486--810 and \>810 US dollar, USD), and ophthalmologic OPD before the index date. According to the different viral hepatitis infection, viral hepatitis cohorts were grouped into five groups: only hepatitis A virus infection (HAV; *ICD-9-CM* 070.0x and 070.1x), only hepatitis B virus infection (HBV; *ICD-9-CM* 070.2x, 070.3x, and V02.61), only hepatitis C virus infection (HCV; *ICD-9-CM* 070.41, 070.44, 070.51, 070.54, 070.7, 070.70, 070.71 and V02.62), HBV combined HCV infection, and other (non-A, non-B, non-C hepatitis of viral cause).

Statistical Analysis {#s1-4}
--------------------

The incidence (per 10,000) and prevalence (per 10,000) of alcoholic liver disease (ALD; *ICD-9-CM* 571.0x-571.3x, except viral hepatitis infection), and different viral hepatitis type were calculated from 2000 to 2011. A chi-square test was used for the difference of demographic characteristics between the viral hepatitis cohort and comparison cohort. A *t*-test was used for the difference of the mean OPD visit for ophthalmology between the two cohorts. The incidence of uveitis was counted in 2 cohorts (per 10,000 person-years). The risk of uveitis in viral hepatitis cohort comprised with comparison cohort was stratified by age group, gender, occupation, and monthly income using Cox proportional hazard regression. A multivariable Cox model was adjusted for continuous age, gender, occupation, monthly income, and OPD visits for ophthalmology before the index date. The association between uveitis and different viral hepatitis type was estimated.

In further analysis, we also assessed the association between uveitis and cirrhosis in patients with viral hepatitis infection. Because we intended to know whether cirrhosis is an extra risk for uveitis in addition to hepatitis, we used "with or without cirrhosis" as an independent variable in the Cox model and different types of hepatitis as grouping variables. By this way, the contribution of cirrhosis to the occurrence of uveitis can be identified in different types of hepatitis. All analyses were performed using SAS statistical software, version 9.4 for Windows (SAS Institute, Cary, NC). The level of significance was set at *P* \< 0.05 at 2-tailed test.

Results {#s2}
=======

The prevalence of all forms of hepatitis in Taiwan has generally increased from 2000 to 2011 (Figure [1](#F1){ref-type="fig"}A). The prevalence of viral hepatitis has also generally increased (Figure [1](#F1){ref-type="fig"}B). However, the incidence of viral hepatitis in Taiwan has generally decreased from 2000 to 2011 (Figure [1](#F1){ref-type="fig"}C). Among them, the prevalence of ALD and only HBV, only HCV, and HBV combined HCV infection increased by year, except HAV and other viral infections. The highest change of prevalence was in only HCV infection (∆2.08 = \[63.73--20.66\]/20.66), followed by only HBV infection (∆1.77), HBV combined HCV infection (∆1.67), and ALD (∆0.60). But the incidence of ALD and each viral hepatitis type infection decreased by year (Figure [1](#F1){ref-type="fig"}A). The highest change of incidence was in other viral infection (∆−0.84), followed by only HAV infection (∆−0.72), only HBV infection (∆−0.65), only HCV infection (∆−0.56), ALD (∆−0.49), and HBV combined HCV infection (∆−0.04).

![**A.** The prevalence of all forms of hepatitis in Taiwan has generally increased from 2000 to 2011. **B.** The prevalence of different viral hepatitis in Taiwan has generally increased from 2000 to 2011. **C.** The incidence of different viral hepatitis in Taiwan has generally decreased from 2000 to 2011.](retina-36-2391-g001){#F1}

In this retrospective cohort study, we selected 17,389 patients with viral hepatitis infection and 34,778 age, gender, monthly income, occupation, ophthalmologic OPD, and index-year--matched comparison. In patients infected with viral hepatitis, there were more men than women (56.8% vs. 43.2%) and the mean age was 46.0 years (SD = 15.0; Table [1](#T1){ref-type="table"}).

###### 

Demographic Characteristics Between Viral Hepatitis Infection and Comparison Cohort

![](retina-36-2391-g002)

The mean follow-up years were 6.27 (SD = 3.30) and 6.13 (SD = 3.31) in hepatitis and comparison cohort, respectively. There was a significant difference of mean follow-up years between the two cohorts because of a large sample size. The mean follow-up years were 6.24, 6.22, 5.70, 6.01, and 6.80 (SD = 3.16, 3.26, 3.25, 3.27, and 3.35, respectively) in only HAV, only HBV, only HCV, HCV and HBV, respectively, and other subcohort. During the follow-up period, the incidence of uveitis in the viral hepatitis infection cohort was 1.29 times greater than that of the comparison cohort (8.53 vs. 6.61 per 10,000 person-years; Table [2](#T2){ref-type="table"}). After adjusting for continuous age, gender, occupation, monthly income, and ophthalmologic OPD visits before the index date, the risk of uveitis in the viral hepatitis infection cohort was 1.30 times than that of the comparison cohort (95% confidence interval \[CI\] = 1.01--1.69). No matter at which age group the patients were in, gender, occupation, and monthly income, viral hepatitis infection patients had a higher risk of uveitis than comparisons, except for those at age 40 to 49 years, but did not reach statistical significance. Only men aged 20 to 39 years and those with monthly income at \<486 USD presented a significantly higher risk of uveitis. The fact that uveitis events occurred more in men (N = 161) than in women (N = 73). The hepatitis infection-associated uveitis risk only in male patients presented significantly higher (HR = 1.35, 95% CI = 1.01--1.89). However, the interaction between gender and hepatitis for risk of uveitis was not significant (*P* = 0.53 in multivariable model).

###### 

Incidence and HR of Uveitis in Viral Hepatitis Infection Patients Compared With Comparisons Stratified by Gender, Age, Occupation, and Monthly Income
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In different viral hepatitis type infections, the higher incidence of uveitis was observed in patients with HBV and HCV coinfection (19.98 per 10,000 person-years; Table [3](#T3){ref-type="table"}), only HAV (19.55 per 10,000 person-years), only HCV infection (14.13 per 10,000 person-years), other causes of hepatitis (10.68 per 10,000 person-years), and HBV infection (5.96 per 10,000 person-years). In our multivariable model, a significantly higher risk of uveitis was only observed in patients with HBV and HCV coinfection (hazard ratio \[HR\] = 2.88, 95% CI = 1.07--7.78), patients with only HCV infection (HR = 1.75; 95% CI = 1.10--2.79), and patients with other hepatitis infection (HR = 1.57; 95% CI = 1.05--2.36) compared with the control cohort. In other hepatitis infection, there was almost unspecified viral hepatitis without mention of hepatic coma.

###### 

Incidence and HR of Uveitis in Different Viral Hepatitis Type Infection

![](retina-36-2391-g004)

The association between uveitis and liver cirrhosis among different types of viral hepatitis infection is presented in Table [4](#T4){ref-type="table"}. Compared with viral hepatitis patients without liver cirrhosis, hepatitis infection patients with liver cirrhosis had a higher risk in the multivariable model but did not attach statistical difference (HR = 1.29; 95% CI = 0.77--2.17).

###### 

Association Between Uveitis and Liver Cirrhosis in Cox Proportional Model Among Different Viral Hepatitis Infection

![](retina-36-2391-g005)

Discussion {#s3}
==========

Uveitis is one of the leading causes of visual impairment and is responsible for 5% to 20% of legal blindness in Western countries and approximately 25% of blindness in the developing world.^[@R13],[@R14]^ Uveitis can be caused by a remote disease somewhere else. The uvea is rich in blood vessels, so if the immune system is activated in one organ, the inflammatory cells plus cytokines can enter the eyes hematogenously and cause inflammation. Various systemic infective agents have been postulated in the pathogenesis of uveitis, including hepatitis viruses.^[@R1]--[@R7]^

Viral hepatitis is the most common type of hepatitis that causes inflammation of the liver and subsequent liver damage. Viral hepatitis includes hepatitis A, hepatitis B, hepatitis C, hepatitis D, and hepatitis E. Hepatitis B and hepatitis C are the most common in Taiwan.^[@R8]^ In the literature, few published reports have estimated the relationship between viral hepatitis, liver cirrhosis, and the potential risk of uveitis.^[@R1]--[@R7],[@R15],[@R16]^ Grob et al^[@R1]^ demonstrated that 13% of patients with uveitis were sera positive for hepatitis B surface antigen in a study from Switzerland. A survey from England showed 2% of patients with various types of uveitis were sera hepatitis B surface antigen positive.^[@R2]^ There were 32 spontaneous reports of uveitis occurring after hepatitis B vaccine from the National Registry of Drug-Induced Ocular Side Effects, the World Health Organization, and the Food and Drug Administration between 1982 and 2009.^[@R3]^ A pilot study revealed significantly higher aqueous flare values and increased choroid thickness in patients with hepatitis C. The choroidal thickness also increased as the degree of anterior chamber inflammation increases.^[@R4]^

According to our study, the incidence of viral hepatitis in Taiwan has been generally decreased from 2000 to 2011, which may be attributed to active vaccination and public health programs.^[@R8]^ In addition, because of the advances in the medical care and the prolonged life expectancy, the prevalence of viral hepatitis has generally increased according to the NHIRD.

These viral infections could be associated with extrahepatic manifestations with the possibility to infect not only hepatic but also lymphatic cells and to be associated with an extrahepatic comorbidity of an autoimmune and/or lymphoproliferative nature.^[@R17],[@R18]^ Ocular manifestations related to treatment and nontreatment such as dry eye syndrome, Sjögren syndrome, xerophthalmia, Mooren ulcer, cystoid macular edema, ischemic retinopathy, ischemic optic neuropathy, uveitis, scleritis, and Vogt--Koyanagi--Harada disease with hepatitis B or C have been reported.^[@R1]--[@R7],[@R15],[@R19],[@R20]^ Nevertheless, the association between uveitis and viral hepatitis has not been extensively studied to date.

Although rare, atypical ophthalmologic complications associated with interferon treatment, including uveitis, have been reported.^[@R15],[@R16],[@R21],[@R22]^ There were also few case reports of Vogt--Koyanagi--Harada disease occurring during interferon-α and ribavirin therapy for HCV.^[@R19],[@R23]--[@R25]^

Our study concludes that viral hepatitis may increase the risk of subsequent uveitis. The risk of uveitis in the viral hepatitis infection cohort was 1.30-fold in comparison with that of the cohort (95% CI = 1.01--1.69). In the multivariable model, patients with HBV and HCV coinfection had the highest risk (HR = 2.88; 95% CI = 1.07--7.78), followed by only HCV infection (HR = 1.75; 95% CI = 1.10--2.79). Furthermore, viral hepatitis infection complicated with liver cirrhosis had a higher risk in the multivariable model but did not attach statistical difference (HR = 1.29; 95% CI = 0.77--2.17).

The uveitis events were observed more in men (N = 161) than in women (N = 73), which is the reason to demonstrate the relatively higher risk of uveitis in men and not in women. However, the interaction between gender and hepatitis for risk of uveitis was not significant in the multivariable model (*P* = 0.53). It means that the association between uveitis and hepatitis was similar in men and women.

HBV is a 42-nanometer, partially double-stranded DNA virus classified in the Hepadnaviridae family. The HCV is a 55-nanometer, positive-strand RNA virus classified in the Flaviviridae family. HBV can be detected in the eye as a number of studies have revealed hepatitis B surface antigen in tears and aqueous humor of hepatitis B surface antigen seropositive patients.^[@R26]^ Researchers have also detected the presence of HCV RNA in tear fluid.^[@R27]^ Uveitis might be a physiologic immune response to fight an infection within the eye.

The other possible mechanism of comorbidity with uveitis includes the complement-mediated immune pathway leading to granulocyte aggregation within the retinal vasculature, which, in turn, causes the release of inflammatory mediators and uveoretinal inflammation.^[@R28],[@R29]^ Significantly higher levels of immunoglobulin G antiuveal autoantigen with coiled coil domains and ankyrin-repeat autoantibodies were found in patients with panuveitis, compared with healthy controls, indicating that autoimmunity is a common phenomenon in these diseases.^[@R30]^ Hepatitis C virus itself has also been reported to have the capability to modulate genes involved in ocular pathologies.^[@R31]^ The statistical significance of both HBV and HCV increasing the risk of uveitis also suggests that this association exists.

Our study has a few limitations. First, diagnoses of viral hepatitis, liver cirrhosis, and uveitis are identified completely dependent on *ICD* codes. However, Taiwan\'s Bureau of National Health Insurance has established a mechanism to interview patients and it reviews medical charts to verify diagnosis validity and quality of care. Hospitals receive heavy penalties from the National Health Insurance Bureau when discrepancies, overcharging, and malpractice are discovered. Comorbidity between nonuveitic ocular manifestations and uveitis cannot be definitely excluded. However, the diagnostic bias could be lessened because of codes specific for uveitis, Sjögren syndrome, dry eye syndrome, and ischemic retinopathy in NHIRD. Second, these findings may only be related to the Taiwanese population and that other similar studies should be performed in different countries to see if the association holds.

Because the incidence of HBV and HCV is relatively low in western countries, the literature with large case number and similar findings is difficult to obtain. Nevertheless, this also demonstrates the originality of this research. However, more robust evidence from further investigations about different viral infections or hepatic diseases is needed to explain the findings in this study.

In conclusion, this study suggests that viral hepatitis may increase the risk of subsequent uveitis. No matter at which age group, gender, occupation, and monthly income, patients with viral hepatitis infection had a higher risk of uveitis than comparisons, except those in the age group of 40 years to 49 years, but it did not reach statistical significance. The association between gender and hepatitis for risk of uveitis was not significant in multivariable model. Patients with HBV and HCV coinfection had the highest risk of uveitis. Viral hepatitis infection complicated with liver cirrhosis had a higher risk but did not attach statistical difference. In patients with HCV and/or HBV infection, the symptomatic condition of uveitis should be alerted. Although these epidemiologic studies yielded informative results, the underlying mechanisms and the host\'s genetic factors remain to be investigated.
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